New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The efficacy of traditional triple therapy has been decreased to such an unacceptable level
as 70% in many areas. The study is based on the hypothesis: the most important factors which
influence the effect of Helicobacter pylori (H. pylori) eradication included acid suppression
intensity and sensitivity of antibiotics. So the investigators chose dual therapy because it
is simple and verified to be useful. Rabeprazole, as a new proton pump inhibitor (PPI), is
reported to be less susceptible to the influence of genetic polymorphisms for CYP2C19. So it
has a greater and faster acid suppression effect compared to other PPIs. Amoxicillin is one
of effective antibiotics to H. pylori with few side effects. The antibiotic resistance of
Amoxicillin is no more than 3% in China. The purpose of our trial is to evaluate and compare
the efficacy and safety of dual therapy regimens with different doses of Rabeprazole for
initial treatment of H. pylori infection.